OGGIONI, NORBERTO
 Distribuzione geografica
Continente #
NA - Nord America 8.486
EU - Europa 4.510
AS - Asia 1.672
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 21
SA - Sud America 16
AF - Africa 13
Totale 14.745
Nazione #
US - Stati Uniti d'America 8.310
DE - Germania 895
SE - Svezia 841
CN - Cina 820
IE - Irlanda 667
IT - Italia 556
UA - Ucraina 526
RU - Federazione Russa 347
GB - Regno Unito 253
SG - Singapore 244
HK - Hong Kong 210
CA - Canada 170
VN - Vietnam 131
FI - Finlandia 115
AT - Austria 99
IN - India 69
DK - Danimarca 63
FR - Francia 63
KR - Corea 55
ID - Indonesia 40
JP - Giappone 32
TR - Turchia 26
NL - Olanda 25
MY - Malesia 21
EU - Europa 18
BE - Belgio 17
NZ - Nuova Zelanda 17
IR - Iran 15
PL - Polonia 12
AU - Australia 10
BR - Brasile 10
EG - Egitto 8
ES - Italia 7
CZ - Repubblica Ceca 6
BG - Bulgaria 4
CL - Cile 4
HR - Croazia 4
HU - Ungheria 4
MX - Messico 4
AE - Emirati Arabi Uniti 3
RS - Serbia 3
A1 - Anonimo 2
GT - Guatemala 2
LB - Libano 2
NG - Nigeria 2
PT - Portogallo 2
SA - Arabia Saudita 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
KW - Kuwait 1
MA - Marocco 1
PE - Perù 1
TW - Taiwan 1
VE - Venezuela 1
Totale 14.745
Città #
Ann Arbor 1.879
Woodbridge 819
Chandler 706
Dublin 651
Jacksonville 543
Houston 523
Fairfield 455
Wilmington 446
Frankfurt am Main 430
Dearborn 424
Ashburn 322
New York 266
Princeton 244
Milan 229
Hong Kong 193
Seattle 174
Nanjing 173
Boardman 170
Cambridge 136
Singapore 120
Shanghai 108
Vienna 99
Lachine 89
Dong Ket 78
Altamura 73
Lawrence 71
Beijing 64
Nanchang 59
Guangzhou 58
Andover 42
Fremont 42
Grafing 40
Jakarta 40
Shenyang 40
Jinan 35
Toronto 35
Jiaxing 34
Nürnberg 33
San Diego 31
Falls Church 26
Ottawa 25
Tianjin 25
Daejeon 24
Helsinki 23
Kunming 23
Mountain View 23
Hangzhou 22
Hebei 22
Pune 22
Zhengzhou 22
Changsha 21
Los Angeles 21
Sacramento 19
Brussels 17
Leawood 16
Chicago 14
Ningbo 14
Edmonton 13
Huizen 13
Bergamo 12
Norwalk 12
Pasir Mas 12
Regensburg 12
Shinjuku 12
Phoenix 11
Rome 11
Taizhou 11
Auburn Hills 10
Hefei 10
Kiev 9
San Mateo 9
Yongin-si 9
Carate Brianza 8
Codroipo 8
London 8
Philadelphia 8
Cagliari 7
Canazei 7
Changchun 6
Detroit 6
Lissone 6
Mainz 6
Washington 6
Wuhan 6
Ankara 5
Auckland 5
Clarks Summit 5
Frederick 5
Haikou 5
Laurel 5
Redmond 5
Secaucus 5
Seoul 5
Suwon 5
Tappahannock 5
Tokyo 5
Fuzhou 4
Induno Olona 4
Kocaeli 4
Lanzhou 4
Totale 10.677
Nome #
Age-related changes in the function and structure of the peripheral sensory pathway in mice 289
Global transcriptomic profile of dorsal root ganglion and physiological correlates of cisplatin-induced peripheral neuropathy 281
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 277
Extracorporeal photochemotherapy reduces the severity of Lewis rat experimental allergic encephalomyelitis through a modulation of the function of peripheral blood mononuclear cells 260
Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy 260
Neuropathic pain is reduced in acid sphingomyelinase deficient mice. 226
Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: New useful ready-to-use animal models 226
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 210
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 194
Effect on the peripheral nervous system of systemically administered dimethylsulfoxide in the rat: a neurophysiological and pathological study 192
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 191
Calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity 190
Bortezomid-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. 187
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 185
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 179
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 178
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse 176
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats 175
Effects of Islet Transplantation and Mesenchymal Stem Cell Co-Transplantation in the Protection of Diabetic Neuropathy in Streptozotocin-Induced Diabetic Rats 173
CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats 172
The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity 171
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 167
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 166
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth 165
Therapeutic Administration of Mesenchymal Stem Cells Abrogates the Relapse Phase in Chronic Relapsing-Remitting EAE 160
Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model 159
Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor 158
Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity 157
Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies 157
In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™) 156
Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats 156
Toward the identification of neuroprotective agents: G-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising SIGMA1 receptor agonist 152
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies 151
Lipoplatin tm: a less neurotoxic formulation of cisplatin 151
Bortezomib-Induced Peripheral Neurotoxicity: a Preclinical Model to Study Neuropathic Pain in Rat 150
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 150
Islet transplantation and insulin administration relieve long-term complications and rescue the residual endogenous pancreatic β cells 149
Platinum-taxane combination chemotherapy: General and peripheral neurotoxicity of their combined administration in the rat 147
Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration 147
Granulocytes in actively induced Lewis rat EAE 144
Platinum-Taxane combination chemotherapy: assessment of electrophysiologic pathologic and morphometric fetures in chronic wistar rat models 144
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity 143
Cr4056: a novel potent anti-nociceptive agent for several animal models of neuropathic pain 142
Bortezomib-induced peripheral neurotoxicity: A neurophysiological study in a rat model 141
Continuous Buprenorphine Delivery Effect in Streptozotocine-Induced Painful Diabetic Neuropathy in Rats 140
Reply to a comment paper on the published paper by canta, a. Et al: “calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity”—antioxidants 2020, 9, 594 139
Platinum-taxane combination chemotherapy: Description of the first study to assess the general and peripheral neurotoxicity of their combined administration in the rat 138
Erythropoietin both protects from and reverses experimental diabetic neuropathy 138
Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis 136
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 136
Actively induced EAE in Lewis rats: Characterization of spleen and spinal cord infiltrating lymphocytes by flow cytometry during the course of the disease 134
Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis 132
Immunomodulating effects of extracorporeal photochemotherapy in rat experimental allergic encephalomyelitis 132
The role of the complete Freund’s adjuvant and neutrophils in actively induced Lewis rat EAE 131
Valproate protective effects on cisplatin-induced peripheral neuropathy: An in vitro and in vivo study 130
Regression of diabetic complications by islet transplantation in the rat 130
Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system 126
Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy 125
Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice 124
Antibody Against Tumor Necrosis Factor-α Reduces Bortezomib-induced Allodynia in a Rat Model 123
Multimodal experimental approach to the study of human neurological diseases 123
BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY: STUDY OF PROTEASOME INHIBITION AND MICROTUBULE STABILIZATION MECHANISMS IN RAT MODEL 120
Organic cation transporter 2 mRNA expression in dorsal root ganglia neurons 119
Ethoxyquin is effective in preventing cisplatin-induced painful peripheral neuropathy in rats 118
ANALGELSIC EFFECT OF BUPRENORPHINE IN AN EXPERIMENTAL MODEL OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY 118
A Possible role of OCT2 gene in the development of peripheral neurotoxicity induced by cisplatin 118
Effect of preventive and therapeutic treatment of ghrelin agonist HM01 on the peripheral neurotoxicity induced by bortezomib in wistar rats. 117
Characterization of spleen and spinal cord infiltrating lymphocytes during actively induced EAE in Lewis rats. 116
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy 114
Morphometrical characterization of DRG alterations induced by cisplatin and bortezomib in several mice models 114
Pain-related behaviour and analgesic effect of gabapentin in an experimental model of bortezomib-induced neuropathic pain 113
Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis 112
Effect of proteasome inhibition on the central and peripheral nervous system 112
CISPLATIN, EPOTHILONE B AND BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHIES: A NEUROPHYSIOLOGICAL STUDY IN THE MOUSE. 111
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 111
Preventive treatment with anti-rat neutrophil serum affects the relapsing phase in Dark Agouti EAE rats 110
Bortezomib-induced neuropathic pain: evaluation of antinociceptive effect of a new analgesic compound 108
Characterization of Glutamate Transporters in Peripheral Nervous System. 107
Oxaliplatin-Induced Peripheral Neurotoxicity: Morphological Characterization In Different Mouse Strains 107
The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats 106
Effect of different chronic treatment modalities on the peripheral neurotoxicity of sagopilone in rats: a multimodal analysis 102
Functional recovery with syngeneically transplanted microcapsulated pancreatic islets in streptozotocin-induced diabetic rats. 101
Macrophage infiltration in different preclinical models of chemotherapy-induced peripheral neurotoxicity 101
Effects of palmitoylethanolamide (pea) in cisplatin-induced peripheral neuropathy in mice. 98
Neutrophil contribution and immunoglobulin effect in Dark Agouti Experimental Autoimmune Encephalomyelitis. 98
EXPRESSION OF TRPV1 AND CGRP IN SPINAL PRIMARY AFFERENT NEURONS IN A RAT MODEL OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY TREATED WITH ANALGESICS 97
Characterization of the neurotoxicity and antineoplastic activity of bortezomib in a new myeloma-bearing murine model. 94
Neurotoxicity ad neuropathic pain induced by Bortezomib: evaluation of peripheral nerve fibres from a clinical to an ultrastructural level. 93
Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain 91
STANDARD AND ADVANCED NEUROPHYSIOLOGY SET UP IN MOUSE MODELS: SENSORY RECORDINGS AND NERVE EXCITABILITY TESTING OF THE CAUDAL NERVE. 91
Evaluation of the neuroprotective effect of acetyl-l-carnitine in myeloma-bearing mice treated with bortezomib 90
Biodistrubution and toxicology of two PFCs intravenously injected in rats 89
CHARACTERIZATION OF PERIPHERAL NEUROPATHY INDUCED BY CHRONIC CISPLATIN ADMINISTRATION IN SEVERAL MICE MODELS 88
Neurotoxicity and neuropatic pain induced by Bortezomib:evaluation of peripheral nerve fibres from a clinical to an ultrastructural level 86
STUDY OF THE CALCITONIN GENE-RELATED PEPTIDE-POSITIVE INTRAEPIDERMAL NERVE FIBERS IN A RAT MODEL OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY 85
The part of the Complete Freund’s Adjuvant in actively induced Experimental Autoimmune Encephalomyelitis in Lewis rat. 82
L-serine supplementation suppresses the formation of neurotoxic deoxysphingolipids and improves neuropathy in a type 1 diabetic rat model 81
An innovative traslational approach to oxaliplatin induced peripheral neurotoxicity in animal models: nerve excitability testing. 81
Topiramate neuroprotectant effects against oxaliplatin induced peripheral neurotoxicity 81
CHARACTERIZATION OF BORTEZOMIB- INDUCED PERIPHERAL NEUROPATHY IN EXPERIMENTAL ANIMAL MODELS 80
Totale 14.101
Categoria #
all - tutte 45.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.754


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.589 0 186 210 184 261 366 486 186 265 212 199 34
2020/20212.346 128 76 259 252 205 197 265 197 205 194 132 236
2021/20221.395 81 139 137 127 96 142 65 76 57 116 102 257
2022/20232.668 297 735 235 260 199 431 34 139 214 30 52 42
2023/20242.035 65 62 79 67 274 536 351 89 101 40 23 348
2024/2025369 283 86 0 0 0 0 0 0 0 0 0 0
Totale 15.633